Stroke risk assessment in atrial fibrillation: Risk factors and markers of atrial myopathy

Nature Reviews Cardiology

Volumn 13, Issue 9, 2016, Pages 549-559

  Calenda, Brandon W ^a   Fuster, Valentin ^a   Halperin, Jonathan L ^a   Granger, Christopher B ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BIOLOGICAL MARKER; NATRIURETIC FACTOR; TROPONIN;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; HEART ATRIUM APPENDAGE; HEART ATRIUM ENLARGEMENT; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; LOW RISK PATIENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SLEEP DISORDERED BREATHING; BLOOD; BLOOD CLOTTING; CLINICAL DECISION MAKING; COMPLICATION; DECISION SUPPORT SYSTEM; DIAGNOSTIC IMAGING; FIBROSIS; HEART ATRIUM; HEART ATRIUM REMODELING; METABOLISM; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS;

ATRIAL FIBRILLATION; ATRIAL REMODELING; BIOMARKERS; BLOOD COAGULATION; CLINICAL DECISION-MAKING; DECISION SUPPORT TECHNIQUES; FIBROSIS; HEART ATRIA; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 84978173295     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2016.106     Document Type: Review

References (90)

1. January C. T, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/.American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 64, e1-e76 (2014).
2. Camm A. J, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed With Special contribution of the European Heart Rhythm Association. Eur. Heart J. 33, 2719-2747 (2012).
3. Keogh C, Wallace E, Dillon C, Dimitrov B. D, & Fahey T. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-Analysis. Thromb. Haemost. 106, 528-538 (2011).
4. Singer D. E, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J. Am. Heart Assoc. 2, e000250 (2013).
5. van den Ham H. A, Klungel O. H, Singer D. E, Leufkens H. G, & van Staa T. P. Comparative performance of ATRIA, CHADS2, and CHA2DS2 VASc risk scores predicting stroke in patients with atrial fibrillation: results from a National Primary Care Database. J. Am. Coll. Cardiol. 66, 1851-1859 (2015).
6. Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur. Heart J. 34, 2731-2738 (2013).
7. Kottkamp H. Fibrotic atrial cardiomyopathy: a specific disease/syndrome supplying substrates for atrial fibrillation, atrial tachycardia, sinus node disease, AV node disease, and thromboembolic complications. J. Cardiovasc. Electrophysiol. 23, 797-799 (2012).
8. Benjamin E. J, D'Agostino R. B, Belanger A. J, Wolf P. A, & Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 92, 835-841 (1995).
9. Abhayaratna W. P, et al. Left atrial size: physiologic determinants and clinical applications. J. Am. Coll. Cardiol. 47, 2357-2363 (2006).
10. Kuppahally S. S, et al. Left atrial strain and strain rate in patients with paroxysmal and persistent atrial fibrillation: relationship to left atrial structural remodeling detected by delayed-enhancement MRI. Circ. Cardiovasc. Imaging 3, 231-239 (2010).
11. Saha S. K, et al. Global left atrial strain correlates with CHADS2 risk score in patients with atrial fibrillation. J. Am. Soc. Echocardiogr. 24, 506-512 (2011).
12. Daccarett M, et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J. Am. Coll. Cardiol. 57, 831-838 (2011).
13. Boriani G, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of 10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur. Heart J. 35, 508-516 (2014).
14. Turakhia M. P, et al. Atrial fibrillation burden and short-Term risk of stroke: case-crossover analysis of continuously recorded heart rhythm from cardiac electronic implanted devices. Circ. Arrhythm. Electrophysiol. 8, 1040-1047 (2015).
15. Hijazi Z, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long term Anticoagulation Therapy (RE LY) substudy. Circulation 125, 1605-1616 (2012).
16. Hijazi Z, et al. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart http://dx.doi.org/10.1136/.heartjnl-2015-308887 (2016).
17. Hijazi Z, et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 129, 625-634 (2014).
18. Hijazi Z, et al. N terminal pro B type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J. Am. Coll. Cardiol. 61, 2274-2284 (2013).
19. Hijazi Z, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur. Heart J. 37, 1582-1590 (2016).
20. Holmes D. R. Jr et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-Term warfarin therapy: the PREVAIL trial. J. Am. Coll. Cardiol. 64, 1-12 (2014).
21. Holmes D. R, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374, 534-542 (2009).
22. Corradi D. Atrial fibrillation from the pathologist's perspective. Cardiovasc. Pathol. 23, 71-84 (2014).
23. Corradi D, Callegari S, Maestri R, Benussi S, & Alfieri O. Structural remodeling in atrial fibrillation. Nat. Clin. Pract. Cardiovasc. Med. 5, 782-796 (2008).
24. Mahida S. Genetic discoveries in atrial fibrillation and implications for clinical practice. Arrhythm. Electrophysiol. Rev. 3, 69-75 (2014).
25. Balouch M. A, Kolek M. J, & Darbar D. Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathways. Glob. Cardiol. Sci. Pract. 2014, 24-36 (2014).
26. Al Khatib S. M, et al. Rate-And rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann. Intern. Med. 160, 760-773 (2014).
27. Healey J. S, et al. Subclinical atrial fibrillation and the risk of stroke. N. Engl. J. Med. 366, 120-129 (2012).
28. Martin D. T, et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur. Heart J. 36, 1660-1668 (2015).
29. Lip G. Y, Nieuwlaat R, Pisters R, Lane D. A, & Crijns H. J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137, 263-272 (2010).
30. Chao T. F, et al. Using the CHA2DS2 VASc score for refining stroke risk stratification in low-risk Asian patients with atrial fibrillation. J. Am. Coll. Cardiol. 64, 1658-1665 (2014).
31. Lip G. Y, et al. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide cohort study. Chest 146, 1337-1346 (2014).
32. Taillandier S, et al. Prognosis in patients with atrial fibrillation and CHA2DS2 VASc Score = 0 in a community-based cohort study. J. Cardiovasc. Electrophysiol. 23, 708-713 (2012).
33. Potpara T. S, et al. Reliable identification of truly low thromboembolic risk in patients initially diagnosed with lone atrial fibrillation: the Belgrade atrial fibrillation study. Circ. Arrhythm. Electrophysiol. 5, 319-326 (2012).
34. Friberg L, Skeppholm M, & Terent A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2 VASc score of 1. J. Am. Coll. Cardiol. 65, 225-232 (2015).
35. Olesen J. B, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342, d124 (2011).
36. Lip G. Y, Skjoth F, Nielsen P. B, & Larsen T. B. Non valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2 VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb. Haemost. 114, 826-834 (2015).
37. Olesen J. B, & Torp-Pedersen C. Stroke risk in atrial fibrillation: do we anticoagulate CHADS2 or CHA2DS2 VASc 1, or higher?. Thromb. Haemost. 113, 1165-1169 (2015).
38. Giugliano R. P, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369, 2093-2104 (2013).
39. Granger C. B, et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981-992 (2011).
40. Patel M. R, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883-891 (2011).
41. Marcucci M, et al. Stroke and bleeding risk co distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. Am. J. Med. 127, 979-986.e2 (2014).
42. Olesen J. B, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ?real world? nationwide cohort study. Thromb. Haemost. 106, 739-749 (2011).
43. Friberg L, Rosenqvist M, & Lip G. Y. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125, 2298-2307 (2012).
44. Glotzer T. V, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ. Arrhythm. Electrophysiol. 2, 474-480 (2009).
45. Suzuki T, et al. Echocardiographic predictors of frequency of paroxysmal atrial fibrillation (AF) and its progression to persistent AF in hypertensive patients with paroxysmal AF: results from the Japanese Rhythm Management Trial II for Atrial Fibrillation (J RHYTHM II Study). Heart Rhythm 8, 1831-1836 (2011).
46. Marrouche N. F, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 311, 498-506 (2014).
47. Ganesan A. N, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-Analysis. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/.ehw007 (2016).
48. Steinberg B. A, et al. Higher risk of death and stroke in patients with persistent versus paroxysmal atrial fibrillation: results from the ROCKET AF Trial. Eur. Heart J. 36, 288-296 (2015).
49. Vanassche T, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-Treated patients in ACTIVE A and AVERROES. Eur. Heart J. 36, 281-288 (2015).
50. Senoo K, Lip G. Y, Lane D. A, Buller H. R, & Kotecha D. Residual risk of stroke and death in anticoagulated patients according to the type of atrial fibrillation: AMADEUS Trial. Stroke 46, 2523-2528 (2015).
51. Szymanski F. M, et al. Obstructive sleep apnoea in patients with atrial fibrillation: prevalence, determinants and clinical characteristics of patients in Polish population. Kardiol. Pol. 72, 716-724 (2014).
52. Marin J. M, Carrizo S. J, Vicente E, & Agusti A. G. Long-Term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365, 1046-1053 (2005).
53. Yaranov D. M, et al. Effect of obstructive sleep apnea on frequency of stroke in patients with atrial fibrillation. Am. J. Cardiol. 115, 461-465 (2015).
54. Chang C. C, et al. Obstructive sleep apnea and the risk of ischemic stroke in patients with atrial fibrillation. Int. J. Cardiol. 181, 144-146 (2015).
55. Roldan V, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2 VASc stroke stratification risk scores for atrial fibrillation?. Thromb. Haemost. 109, 956-960 (2013).
56. Piccini J. P, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 127, 224-232 (2013).
57. Hohnloser S. H, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur. Heart J. 33, 2821-2830 (2012).
58. Lin W. Y, et al. Impact of renal dysfunction on clinical outcome in patients with low risk of atrial fibrillation. Circ. J. 78, 853-858 (2014).
59. Wiese S, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 102, 3074-3079 (2000).
60. Yoshioka K, et al. A score for predicting paroxysmal atrial fibrillation in acute stroke patients: iPAB score. J. Stroke Cerebrovasc. Dis. 24, 2263-2269 (2015).
61. Shibazaki K, et al. Brain natriuretic peptide level on admission predicts recurrent stroke after discharge in stroke survivors with atrial fibrillation. Clin. Neurol. Neurosurg. 127, 25-29 (2014).
62. The Stroke Prevention Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann. Intern. Med. 116, 6-12 (1992).
63. Ayirala S, Kumar S, O'Sullivan D. M, & Silverman D. I. Echocardiographic predictors of left atrial appendage thrombus formation. J. Am. Soc. Echocardiogr. 24, 499-505 (2011).
64. Faustino A, et al. Which method of left atrium size quantification is the most accurate to recognize thromboembolic risk in patients with non-valvular atrial fibrillation?. Cardiovasc. Ultrasound 12, 28 (2014).
65. Osranek M, et al. Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: three-decade follow up. Eur. Heart J. 26, 2556-2561 (2005).
66. Barnes M. E, et al. Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation. Mayo Clin. Proc. 79, 1008-1014 (2004).
67. Shih J. Y, et al. Association of decreased left atrial strain and strain rate with stroke in chronic atrial fibrillation. J. Am. Soc. Echocardiogr. 24, 513-519 (2011).
68. Watanabe A, et al. Left atrial remodeling assessed by transthoracic echocardiography predicts left atrial appendage flow velocity in patients with paroxysmal atrial fibrillation. Int. Heart J. 57, 177-182 (2016).
69. Bayar N, et al. Evaluation of the association between stroke/transient ischemic attack and atrial electromechanical delay in patients with paroxysmal atrial fibrillation. Anatol. J. Cardiol. http://dx.doi.org/.10.5152/AnatolJCardiol.2015.6424 (2015).
70. Savelieva I, Bajpai A, & Camm A. J. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann. Med. 39, 371-391 (2007).
71. Di Biase L, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation?. Results from a multicenter study. J. Am. Coll. Cardiol. 60, 531-538 (2012).
72. Khurram I. M, et al. Relationship between left atrial appendage morphology and stroke in patients with atrial fibrillation. Heart Rhythm 10, 1843-1849 (2013).
73. Goldman M. E, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J. Am. Soc. Echocardiogr. 12, 1080-1087 (1999).
74. Hirsh B. J, Copeland-Halperin R. S, & Halperin J. L. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. J. Am. Coll. Cardiol. 65, 2239-2251 (2015).
75. Woods C. E, & Olgin J. Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation. Circ. Res. 114, 1532-1546 (2014).
76. Sanna T, et al. Cryptogenic stroke and underlying atrial fibrillation. N. Engl. J. Med. 370, 2478-2486 (2014).
77. Binici Z, Intzilakis T, Nielsen O. W, Kober L, & Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation 121, 1904-1911 (2010).
78. Chong B. H, et al. Frequent premature atrial complexes predict new occurrence of atrial fibrillation and adverse cardiovascular events. Europace 14, 942-947 (2012).
79. Dewland T. A, et al. Atrial ectopy as a predictor of incident atrial fibrillation: a cohort study. Ann. Intern. Med. 159, 721-728 (2013).
80. Lin C. Y, et al. Prognostic significance of premature atrial complexes burden in prediction of long-Term outcome. J. Am. Heart Assoc. 4, e002192 (2015).
81. Larsen B. S, Kumarathurai P, Falkenberg J, Nielsen O. W, & Sajadieh A. Excessive atrial ectopy and short atrial runs increase the risk of stroke beyond incident atrial fibrillation. J. Am. Coll. Cardiol. 66, 232-241 (2015).
82. Kamel H, et al. Paroxysmal supraventricular tachycardia and the risk of ischemic stroke. Stroke 44, 1550-1554 (2013).
83. Brembilla-Perrot B, & Delobelle J. Prevalence of stroke among patients with paroxysmal supraventricular tachycardia. Pacing Clin. Electrophysiol. 36, 180-186 (2013).
84. Mahabadi A. A, et al. Association of epicardial adipose tissue and left atrial size on non-contrast CT with atrial fibrillation: the Heinz Nixdorf Recall Study. Eur. Heart J. Cardiovasc. Imaging 15, 863-869 (2014).
85. Qureshi W, et al. Risk factors for atrial fibrillation in patients with normal versus dilated left atrium (from the Atherosclerosis Risk in Communities Study). Am. J. Cardiol. 114, 1368-1372 (2014).
86. Hirose T, et al. Left atrial function assessed by speckle tracking echocardiography as a predictor of new-onset non-valvular atrial fibrillation: results from a prospective study in 580 adults. Eur. Heart J. Cardiovasc. Imaging 13, 243-250 (2012).
87. Abed H. S, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 310, 2050-2060 (2013).
88. Melgaard L, et al. Assessment of the CHA2DS2 VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA 314, 1030-1038 (2015).
89. Holmes D. R. Jr et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-Analysis. J. Am. Coll. Cardiol. 65, 2614-2623 (2015).
90. Warraich H. J, Gandhavadi M, & Manning W. J. Mechanical discordance of the left atrium and appendage: a novel mechanism of stroke in paroxysmal atrial fibrillation. Stroke 45, 1481-1484 (2014).